Second-line Chemotherapy in Castration Resistant Prostate Cancer
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate the safety of biweekly cabazitaxel for the treatment of
metastatic castration resistant prostate cancer (mCRPC) patients previously treated with
docetaxel containing regimen. The primary endpoint is safety. Secondary endpoints include
time to treatment failure, response rate, overall survival and quality of life.
Phase:
Phase 2
Details
Lead Sponsor:
Tampere University Hospital
Collaborators:
Helsinki University Central Hospital Kuopio University Hospital Seinajoki Central Hospital Turku University Hospital